Bray, 2nd December 2020, Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, has officially launched the expansion of its production line at its Bray facility. The company which has been established in Bray since 1997 currently employs more than 340 employees at the Co. Wicklow facility in which it has invested €20m over the past two years.
The expansion announced today allows for the addition of production, packaging and shipping of two oncology products to the site’s manufacturing portfolio, with Oncology production being a new therapeutic area for the Bray site. Commercial production of the first of these products will start at the end of 2020.
Thomas Wozniewski, Takeda Global Manufacturing & Supply Officer, commented: “This investment shows our commitment to Ireland and the importance as a production location for Takeda. Oncology is one of four Takeda’s core therapeutic areas, and with the new production line we will make our supply chain for both products more robust and flexible, to be prepared also for future growth.”
James Dinniss, Bray Site Head, commented: “Over the past two and half years the teams have demonstrated their experience, perseverance and flexibility to deliver this complex project on time and budget through many challenges, not least the COVID pandemic. We are very excited to start production of these Oncology products for patients who currently have limited options for treatments, and we are proud that the products we make will have a significant impact on their life.”
Tánaiste and Minister for Enterprise, Trade and Employment Leo Varadkar said: “I am pleased to see the expansion of Takeda’s product line in Bray, which will see the plant commence commercial production of two new oncology products. This announcement follows significant investment in the company’s Bray facility, which underscores Takeda’s commitment to County Wicklow. I understand these products will have significant benefits for patients, which is very welcome news.”
IDA Ireland CEO Martin Shanahan said: “I wish to congratulate Takeda on today’s announcement, which is testament to the commitment of the team at the Bray facility where production first began in 1997. Today’s announcement demonstrates Takeda’s continued commitment to Ireland, and I wish them every success with the expansion of the manufacturing portfolio.”
Takeda Ireland – Bray, was established in 1997 as a Solid Oral Dosage Facility, which produces, packs and ships granulates, solid oral dosage tablets and final packaged products to the worldwide markets including the major US, European, Japanese and valuable emerging markets. As of today, Bray produces products for the therapeutic areas of Cardiovascular and Metabolic, Central Nervous System (CNS), Gastrointestinal and Oncology.
Takeda Pharmaceutical Company Limited, a global, values-based, R&D-driven biopharmaceutical leader committed to bringing better health and a brighter future to patients by translating science into life-changing medicines, has been established in Ireland since 1997. Across Ireland, Takeda has commercial operations, corporate services and two manufacturing facilities in Bray and Grange Castle.
Head of Communications & Patient Advocacy, UK and Ireland
Tel: +44 750 095 3471